Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | HOOK |
---|---|---|
09:32 ET | 32398 | 0.797 |
09:34 ET | 3100 | 0.82 |
09:36 ET | 1000 | 0.82 |
09:38 ET | 8139 | 0.8199 |
09:39 ET | 1600 | 0.819 |
09:41 ET | 1200 | 0.8199 |
09:43 ET | 800 | 0.8199 |
09:45 ET | 1000 | 0.8199 |
09:48 ET | 21800 | 0.8101 |
09:50 ET | 7222 | 0.780101 |
09:52 ET | 2600 | 0.8055 |
09:54 ET | 9244 | 0.8199 |
09:56 ET | 600 | 0.8199 |
09:57 ET | 1200 | 0.8199 |
09:59 ET | 800 | 0.8199 |
10:01 ET | 1040 | 0.819 |
10:03 ET | 21818 | 0.782555 |
10:06 ET | 17607 | 0.8099 |
10:08 ET | 2370 | 0.8056 |
10:10 ET | 2800 | 0.8172 |
10:12 ET | 61285 | 0.825 |
10:14 ET | 2200 | 0.83 |
10:15 ET | 7004 | 0.83 |
10:17 ET | 2700 | 0.83 |
10:19 ET | 1050 | 0.8216 |
10:21 ET | 700 | 0.8296 |
10:24 ET | 1808 | 0.8295 |
10:26 ET | 3200 | 0.829 |
10:28 ET | 11261 | 0.8289 |
10:30 ET | 1150 | 0.81725 |
10:32 ET | 1211 | 0.8205 |
10:33 ET | 4794 | 0.8206 |
10:35 ET | 3889 | 0.8206 |
10:37 ET | 2900 | 0.8288 |
10:39 ET | 3000 | 0.8243 |
10:42 ET | 600 | 0.8279 |
10:44 ET | 600 | 0.8277 |
10:46 ET | 1853 | 0.8299 |
10:48 ET | 500 | 0.8299 |
10:50 ET | 600 | 0.8299 |
10:51 ET | 930 | 0.8299 |
10:53 ET | 3800 | 0.8299 |
10:55 ET | 6800 | 0.8299 |
10:57 ET | 2160 | 0.8299 |
11:00 ET | 16412 | 0.8398 |
11:02 ET | 33110 | 0.84 |
11:04 ET | 73652 | 0.8587 |
11:06 ET | 6100 | 0.8586 |
11:08 ET | 8574 | 0.84 |
11:09 ET | 5690 | 0.8452 |
11:11 ET | 10293 | 0.83 |
11:13 ET | 6530 | 0.8495 |
11:15 ET | 13150 | 0.845 |
11:18 ET | 750 | 0.845 |
11:20 ET | 3300 | 0.845 |
11:22 ET | 7873 | 0.845 |
11:24 ET | 4100 | 0.845 |
11:26 ET | 2400 | 0.845 |
11:27 ET | 1500 | 0.842 |
11:29 ET | 8593 | 0.8499 |
11:31 ET | 6100 | 0.8421 |
11:33 ET | 3536 | 0.842 |
11:36 ET | 950 | 0.84595 |
11:38 ET | 3300 | 0.8499 |
11:40 ET | 31110 | 0.8501 |
11:42 ET | 3315 | 0.855 |
11:44 ET | 11000 | 0.855 |
11:45 ET | 9100 | 0.8547 |
11:47 ET | 9209 | 0.8547 |
11:51 ET | 7860 | 0.8501 |
11:54 ET | 5840 | 0.85 |
11:56 ET | 1315 | 0.8587 |
11:58 ET | 500 | 0.8587 |
12:00 ET | 1565 | 0.8587 |
12:02 ET | 71508 | 0.8559 |
12:03 ET | 8765 | 0.8577 |
12:05 ET | 32985 | 0.8578 |
12:07 ET | 3740 | 0.8589 |
12:09 ET | 104518 | 0.875 |
12:12 ET | 5747 | 0.8651 |
12:14 ET | 42332 | 0.87 |
12:16 ET | 200 | 0.869 |
12:18 ET | 7699 | 0.8578 |
12:20 ET | 28318 | 0.865 |
12:21 ET | 4000 | 0.87 |
12:23 ET | 10600 | 0.8564 |
12:25 ET | 3257 | 0.8531 |
12:27 ET | 4521 | 0.86 |
12:30 ET | 2970 | 0.875 |
12:32 ET | 24384 | 0.8625 |
12:34 ET | 4300 | 0.8637 |
12:36 ET | 12500 | 0.8625 |
12:38 ET | 2915 | 0.8607 |
12:39 ET | 2000 | 0.863 |
12:41 ET | 7834 | 0.875 |
12:43 ET | 7060 | 0.875 |
12:45 ET | 7550 | 0.8683 |
12:48 ET | 2306 | 0.875 |
12:50 ET | 13375 | 0.875 |
12:52 ET | 17510 | 0.878 |
12:54 ET | 25900 | 0.8787 |
12:56 ET | 35557 | 0.8865 |
12:57 ET | 32324 | 0.8835 |
12:59 ET | 54769 | 0.875 |
01:01 ET | 13039 | 0.8785 |
01:03 ET | 16070 | 0.8669 |
01:06 ET | 1199 | 0.878 |
01:08 ET | 23645 | 0.8781 |
01:10 ET | 3206 | 0.878767 |
01:12 ET | 5544 | 0.89 |
01:14 ET | 4400 | 0.89 |
01:15 ET | 27256 | 0.885 |
01:17 ET | 9000 | 0.9 |
01:19 ET | 11912 | 0.9 |
01:21 ET | 4345 | 0.898 |
01:24 ET | 16460 | 0.8925 |
01:26 ET | 9600 | 0.8925 |
01:28 ET | 7285 | 0.892701 |
01:30 ET | 38046 | 0.8951 |
01:32 ET | 4200 | 0.8975 |
01:33 ET | 31045 | 0.9095 |
01:35 ET | 11177 | 0.912545 |
01:37 ET | 18659 | 0.91 |
01:39 ET | 57175 | 0.919799 |
01:42 ET | 21539 | 0.929399 |
01:44 ET | 54620 | 0.945 |
01:46 ET | 28212 | 0.9276 |
01:48 ET | 61855 | 0.915 |
01:50 ET | 50833 | 0.9051 |
01:51 ET | 16902 | 0.90505 |
01:53 ET | 45534 | 0.9049 |
01:55 ET | 14200 | 0.9196 |
01:57 ET | 14667 | 0.8975 |
02:00 ET | 2882 | 0.8902 |
02:02 ET | 15698 | 0.9036 |
02:04 ET | 14157 | 0.9051 |
02:06 ET | 10082 | 0.92 |
02:08 ET | 11650 | 0.9122 |
02:09 ET | 7600 | 0.9063 |
02:11 ET | 6935 | 0.92 |
02:13 ET | 6875 | 0.92 |
02:15 ET | 36833 | 0.92 |
02:18 ET | 72481 | 0.9324 |
02:20 ET | 14045 | 0.9324 |
02:22 ET | 20501 | 0.92 |
02:24 ET | 8870 | 0.9175 |
02:26 ET | 5000 | 0.92 |
02:27 ET | 66500 | 0.9205 |
02:29 ET | 29889 | 0.9008 |
02:31 ET | 36873 | 0.8915 |
02:33 ET | 9651 | 0.8803 |
02:36 ET | 45326 | 0.8762 |
02:38 ET | 859 | 0.8903 |
02:40 ET | 33283 | 0.8915 |
02:42 ET | 2100 | 0.9 |
02:44 ET | 65924 | 0.8826 |
02:45 ET | 43307 | 0.8937 |
02:47 ET | 9519 | 0.9047 |
02:49 ET | 4700 | 0.887 |
02:51 ET | 15800 | 0.9022 |
02:54 ET | 12200 | 0.905 |
02:56 ET | 3043 | 0.91 |
02:58 ET | 64220 | 0.8751 |
03:00 ET | 55438 | 0.8859 |
03:02 ET | 1640 | 0.91 |
03:03 ET | 15614 | 0.9003 |
03:05 ET | 6817 | 0.8959 |
03:07 ET | 200 | 0.8959 |
03:09 ET | 2600 | 0.9095 |
03:12 ET | 6600 | 0.9093 |
03:14 ET | 18300 | 0.9099 |
03:16 ET | 55046 | 0.9099 |
03:18 ET | 300 | 0.9099 |
03:20 ET | 6211 | 0.9098 |
03:21 ET | 11857 | 0.9099 |
03:23 ET | 4889 | 0.9003 |
03:25 ET | 5929 | 0.9051 |
03:27 ET | 2950 | 0.9195 |
03:30 ET | 5100 | 0.9139 |
03:32 ET | 12215 | 0.9001 |
03:34 ET | 500 | 0.9001 |
03:36 ET | 800 | 0.9138 |
03:38 ET | 3100 | 0.9137 |
03:39 ET | 600 | 0.9136 |
03:41 ET | 11981 | 0.9156 |
03:43 ET | 1610 | 0.9156 |
03:45 ET | 17708 | 0.9036 |
03:48 ET | 600 | 0.91 |
03:50 ET | 2810 | 0.9122 |
03:52 ET | 22501 | 0.8924 |
03:54 ET | 1182 | 0.8949 |
03:56 ET | 3167 | 0.8924 |
03:57 ET | 3851 | 0.8962 |
03:59 ET | 83316 | 0.8933 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
HOOKIPA Pharma Inc | 79.8M | 0.0x | --- |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.8M |
---|---|
Revenue (TTM) | $20.1M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-1.07 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 4.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -485.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.